Completed PHASE2 INTERVENTIONAL 3-arm NCT00550173

A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer

A Randomized Phase 2 Study Comparing Erlotinib-Pemetrexed, Pemetrexed Alone, and Erlotinib Alone, as Second-Line Treatment for Non-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer

Sponsor: Eli Lilly and Company

Conditions Non-Small-Cell Lung Cancer

Interventions erlotinib pemetrexed

Updated 7 times since 2017 Last updated: Jan 10, 2013 Started: Nov 30, 2007 Primary completion: Jan 31, 2012 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Non-Small-Cell Lung Cancer and is currently completed. Eli Lilly and Company leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United Kingdom , Ahmedabad, India , Barretos, Brazil , Beijing, China , Bhopal, India , Changhua, Taiwan , Chelmsford, United Kingdom , Guildford, United Kingdom , Hyderabaad, India , Ijuí, Brazil and 19 more locations